Literature DB >> 15451567

Activin and follistatin in female reproduction.

Shanthi Muttukrishna1, Dionne Tannetta, Nigel Groome, Ian Sargent.   

Abstract

Activin and follistatin were initially identified in the follicular fluid based on their effects on pituitary FSH secretion in the mid-1980s. It is now evident that activin, follistatin and activin receptors are widely expressed in many tissues where they function as autocrine/paracrine regulators of a variety of physiological processes including reproduction. The major function of follistatin is to bind to activin with high affinity and block activin binding to its receptors. Total activin A and follistatin are also found in the maternal circulation throughout pregnancy. Activin A levels are increased in abnormal pregnancies such as pre-eclampsia, fetal growth restriction and gestational hypertension. The placenta, vascular endothelial cells and activated peripheral mononuclear cells (PBMC) may all contribute to the raised levels of activin A in pre-eclampsia with unaltered follistatin in pre-eclamptic placenta, PBMCs or vascular endothelial cells suggesting the availability of 'free' activin A that could be biologically active in these cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15451567     DOI: 10.1016/j.mce.2004.02.012

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  21 in total

1.  Placental and maternal serum activin A in spontaneous and induced labor in late-term pregnancy.

Authors:  L Funghi; M Torricelli; R Novembri; S Vannuccini; G Cevenini; M Di Tommaso; F M Severi; F Petraglia
Journal:  J Endocrinol Invest       Date:  2017-06-13       Impact factor: 4.256

2.  Incomplete activation of peripheral blood dendritic cells during healthy human pregnancy.

Authors:  S Della Bella; S Giannelli; V Cozzi; V Signorelli; M Cappelletti; I Cetin; M L Villa
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

3.  Circulating profile of Activin-Follistatin-Inhibin Axis in women with hypothalamic amenorrhea in response to leptin treatment.

Authors:  Eirini Bouzoni; Nikolaos Perakakis; Christos S Mantzoros
Journal:  Metabolism       Date:  2020-10-10       Impact factor: 8.694

4.  FOXL2 and BMP2 act cooperatively to regulate follistatin gene expression during ovarian development.

Authors:  Kenichi Kashimada; Emanuele Pelosi; Huijun Chen; David Schlessinger; Dagmar Wilhelm; Peter Koopman
Journal:  Endocrinology       Date:  2010-11-17       Impact factor: 4.736

Review 5.  Building pathways for ovary organogenesis in the mouse embryo.

Authors:  Chia-Feng Liu; Chang Liu; Humphrey H-C Yao
Journal:  Curr Top Dev Biol       Date:  2010       Impact factor: 4.897

6.  Estrogen negative feedback on gonadotropin secretion: evidence for a direct pituitary effect in women.

Authors:  N D Shaw; S N Histed; S S Srouji; J Yang; H Lee; J E Hall
Journal:  J Clin Endocrinol Metab       Date:  2010-02-04       Impact factor: 5.958

7.  A variant in the fibrillin-3 gene is associated with TGF-β and inhibin B levels in women with polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Allen R Kunselman; Laurence M Demers; Kathryn G Ewens; Richard S Spielman; Richard S Legro
Journal:  Fertil Steril       Date:  2010-07-14       Impact factor: 7.329

Review 8.  Roles for transforming growth factor beta superfamily proteins in early folliculogenesis.

Authors:  Daniel J Trombly; Teresa K Woodruff; Kelly E Mayo
Journal:  Semin Reprod Med       Date:  2009-02-05       Impact factor: 1.303

Review 9.  TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment.

Authors:  Mai Abdel Mouti; Siim Pauklin
Journal:  Mol Ther       Date:  2021-01-09       Impact factor: 11.454

10.  BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.

Authors:  Tejaswita M Karve; Anju Preet; Rosie Sneed; Clara Salamanca; Xin Li; Jingwen Xu; Deepak Kumar; Eliot M Rosen; Tapas Saha
Journal:  PLoS One       Date:  2012-06-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.